首页> 美国卫生研究院文献>ESMO Open >Safety data from the phase III Japanese ACHIEVE trial: part of an international prospective planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

【2h】

Safety data from the phase III Japanese ACHIEVE trial: part of an international prospective planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

机译：来自日本ACHIEVE III期临床试验的安全性数据：一项国际前瞻性计划中的汇总分析的一部分对6项III期临床试验进行了比较比较了3个月至6个月基于奥沙利铂的辅助化疗治疗III期结肠癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part of this project, we report safety data from the Japanese ACHIEVE study (JFMC47-1202-C3).

机译：背景国际辅助化疗持续时间评估项目研究了以奥沙利铂为基础的辅助化疗的较短持续时间是否与切除III期结肠癌的相同化疗的6个月一样有效。作为该项目的一部分，我们报告了来自日本ACHIEVE研究（JFMC47-1202-C3）的安全性数据。

著录项

期刊名称 ESMO Open
作者
Masahito Kotaka; Takeharu Yamanaka; Takayuki Yoshino; Dai Manaka; Tetsuya Eto; Junichi Hasegawa; Akinori Takagane; Masato Nakamura; Takeshi Kato; Yoshinori Munemoto; Fumitaka Nakamura; Hiroyuki Bando; Hiroki Taniguchi; Makio Gamoh; Manabu Shiozawa; Shigetoyo Saji; Yoshihiko Maehara; Tsunekazu Mizushima; Atsushi Ohtsu; Masaki Mori;
展开▼
作者单位

展开▼
年(卷),期 2018(3),3
年度 2018
页码 e000354
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
colon cancer adjuvant oxaliplatin neuropathy treatment duration creatinine clearance;

机译：结肠癌;奥沙利铂辅助药物;神经病;治疗时间;肌酐清除率;

相似文献

外文文献
中文文献
专利

1. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [J] . Thierry André, Timothy Iveson, Roberto Labianca, Current Colorectal Cancer Reports . 2013,第3期

机译：IDEA（国际辅助化疗持续时间评估）合作：研究III期结肠癌患者用FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月和6个月）方案的辅助治疗持续时间的III期试验的前瞻性联合分析：试验设计与现状
2. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial [J] . Andre Thierry, Vernerey Dewi, Mineur Laurent, Journal of Clinical Oncology . 2018,第15期

机译：三个与6个月的oxaliplatin辅助化疗为III阶段结肠癌患者：无病的生存结果来自随机，开放标签，佐剂国际持续时间评估（想法）法国，第三阶段试验
3. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for PatientsWith Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial (vol 36, pg 1469, 2018) [J] . Andre Journal of Clinical Oncology . 2018,第18期

机译：三个与6个月的oxaliplatin为基于患者的辅助化疗，患者患者III阶段III结肠癌：无病的生存结果来自随机，开放标签，国际持续时间评估的佐剂（想法）法国，III期试验（Vol 36，PG 1469， 2018年）
4. PHASE III COMPARISON OF CARBOPLATIN VERSUS CARBOPLATIN AND DOXORUBICIN FOR THE ADJUVANT TREATMENT OF APPENDICULAR OSTEOSARCOMA: INTERIM ANALYSIS [C] . Katherine Skorupski, Justin Uhl, Stephen Shaw, Annual Conference of the Veterinary Cancer Society . 2009

机译：Carboplatin与Carboplatin和多柔比星的相位III比较，用于辅助骨肉瘤的佐剂治疗：临时分析
5. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [D] . Wang, Ying. 2009

机译：在两个阶段的III期随机临床试验中比较评估生存概率的方法。
6. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [O] . Thierry André, Timothy Iveson, Roberto Labianca, -1

机译：IDEA（国际辅助化疗持续时间评估）合作：III期试验的前瞻性联合分析研究针对III期结肠癌患者的FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月至6个月）方案的辅助治疗的持续时间的III期试验：试验设计与现状
7. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [O] . Thierry André, null null, Timothy Iveson, 2013

机译：IDEA（国际辅助化疗持续时间评估）合作：III期试验的前瞻性联合分析，研究针对III期结肠癌患者的FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月至6个月）方案的辅助治疗的持续时间的III期试验：试验设计与现状

Safety data from the phase III Japanese ACHIEVE trial: part of an international prospective planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

摘要

著录项

相似文献

相关主题

期刊订阅